Comparative Pharmacology
Head-to-head clinical analysis: FELBAMATE versus LAMICTAL ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FELBAMATE versus LAMICTAL ODT.
FELBAMATE vs LAMICTAL ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Felbamate enhances GABAergic transmission and inhibits NMDA receptor activity, likely through interaction with the glycine recognition site.
Lamotrigine is a triazine derivate that stabilizes presynaptic neuronal membranes by blocking voltage-sensitive sodium channels, thereby inhibiting the release of excitatory neurotransmitters (e.g., glutamate). This suppresses neuronal hyperexcitability and prevents seizure spread.
1200-3600 mg/day orally in 3-4 divided doses; initiate at 1200 mg/day and titrate by 600-1200 mg/day every 2 weeks.
Initial 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then increase by 50 mg daily every 1-2 weeks; maintenance 100-200 mg twice daily (200-400 mg/day). For monotherapy or as add-on in epilepsy and bipolar disorder.
None Documented
None Documented
Clinical Note
moderateFelbamate + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Felbamate."
Clinical Note
moderateFelbamate + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Felbamate."
Clinical Note
moderateFelbamate + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Felbamate."
Clinical Note
moderateFelbamate + Clotrimazole
Terminal elimination half-life: 13-23 hours in adults (mean ~20 hours); may be prolonged to 30-40 hours in patients with hepatic impairment or those on enzyme inhibitors; clinical context: requires twice-daily dosing; steady-state reached in 4-5 days
Terminal elimination half-life: 25-39 hours (single dose), 12-22 hours (with enzyme inducers), 30-70 hours (with valproate); clinically relevant for dosing titration to avoid Stevens-Johnson syndrome
Renal: approximately 90% (40-50% unchanged, remainder as metabolites including p-hydroxyfelbamate, 2-hydroxyfelbamate, and felbamate monocarbamate); fecal < 5%
Primarily hepatic metabolism (glucuronidation by UGT1A4); 70-90% excreted renally as metabolites, 2% unchanged; 2-10% fecal
Category C
Category C
Anticonvulsant
Anticonvulsant
"The metabolism of Clotrimazole can be decreased when combined with Felbamate."